通化东宝：人胰岛素注射液上市许可申请获欧洲药品管理局受理
通化东宝2月1日公告，近日，公司获悉，瑞典瑞康生命科学有限公司（Rechon Life Science AB）（以下简称“瑞康公司”）收到了人胰岛素注射液上市许可申请获得欧洲药品管理局受理的批准文件。通化东宝负责提供胰岛素原料药，瑞康公司使用通化东宝提供的胰岛素原料药生产人胰岛素注射液。通化东宝委托其进行欧盟临床相关事宜及注册事宜。截至公告日，通化东宝在该项目中研发投入约7627.71万元。
Statement:
The content of this article does not represent the views of fxgecko website. The content is for reference only and does not constitute investment suggestions. Investment is risky, so you should be careful in your choice! If it involves content, copyright and other issues, please contact us and we will make adjustments at the first time!
Related News
